Overview

Safety of Argatroban Infusion in Conduction Disturbances

Status:
Completed
Trial end date:
2021-05-06
Target enrollment:
Participant gender:
Summary
To determine change of QTc interval during intravenous argatroban infusion in patients undergoing percutaneous coronary intervention (PCI)
Phase:
Phase 4
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma GmbH
Treatments:
Argatroban